GSK flashes positive data for Tesaro drug that could become 7th approved PD-(L)1
A dark horse asset from GlaxoSmithKline’s $5.1 billion buyout of Tesaro is out with its first batch of data in over a year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
